Travere Therapeutics Earnings, Revenue miss In Q3

Investing.com - Travere Therapeutics reported on Wednesday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Travere Therapeutics announced earnings per share of $-1.09 on revenue of $53.50M. Analysts polled by Investing.com anticipated EPS of $-0.94 on revenue of $54.35M.
Travere Therapeutics shares are up 6.41% from the beginning of the year and are trading at $20.76 , down-from-52-week-high.
Travere Therapeutics follows other major Healthcare sector earnings this month
Travere Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.9B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb
Drop an image here or